Citigroup’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Citigroup’s Portfolio SNNA Stock Details SNNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,739	Closed	–	–	7913
2019 Q3	$0	Sell	1,739 -1,953	-53%	-$1.32K	﹤0.01%	7904
2019 Q2	$3K	Sell	3,692 -561	-13%	-$878	﹤0.01%	7599
2019 Q1	$10K	Buy	4,253 +197	+5%	+$534	﹤0.01%	7268
2018 Q4	$9K	Buy	4,056 +382	+10%	+$3.37K	﹤0.01%	7221
2018 Q3	$54K	Buy	+3,674	New	+$58.4K	﹤0.01%	6469
2018 Q2	–	Sell	-2,163	Closed	-$40K	–	7825
2018 Q1	$40K	Buy	2,163 +2,082	+2,570%	+$36.4K	﹤0.01%	6345
2017 Q4	$1K	Buy	+81	New	+$1.71K	﹤0.01%	7517

Other funds holding SNNA

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Private Ocean San Rafael, California $1.13B AUM 11.01% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Citigroup's SNNA Position: Q4 2019 in Review

Citigroup sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q4 2019, closing a stake of 1,739 shares.

Citigroup first reported a position in SNNA in Q4 2017 and held it in 7 quarters. The position peaked at $54K in Q3 2018. 4 funds tracked by Wall St. Rank hold SNNA as of Q4 2019.

Citigroup reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
Citigroup sold 1,739 Sienna Biopharmaceuticals, Inc. shares in Q4 2019.
Citigroup first reported a position in Sienna Biopharmaceuticals, Inc. in Q4 2017 and held it in 7 quarters.
Citigroup's Sienna Biopharmaceuticals, Inc. position peaked at $54K in Q3 2018.
4 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q4 2019.

Based on Citigroup's 13F filing for Q4 2019, filed 12 Feb 2020.